Celadon Pharmaceuticals (CEL)

Sector:

Alternative Investment Instruments

Index:

FTSE AIM All-Share

13.75p
   
  • Change Today:
    -1.75p
  • 52 Week High: 125.00p
  • 52 Week Low: 12.06p
  • Currency: UK Pounds
  • Shares Issued: 68.85m
  • Volume: 332,250
  • Market Cap: £9.47m
  • RiskGrade: 111
  • Beta: 0.11

Celadon starts supplying cannabis for two contracts

By Josh White

Date: Thursday 14 Dec 2023

LONDON (ShareCast) - (Sharecast News) - Medical cannabis specialist Celadon Pharmaceuticals has started supplying its pharmaceutical-grade product to two commercial contracts, first announced on 24 May and 5 September, it said on Thursday.
The AIM-traded firm said the achievement came after completing the latest harvest at its UK-based facility, which would serve as the primary source for fulfilling its commercial obligations.

It said it had commenced periodic invoicing for both contracts, with the first contract guaranteed to generate a minimum revenue of £3m and the second contract expected to yield up to £1.2m in revenue.

Since the announcement of the two contracts, Celadon said it had expanded its portfolio by securing an additional commercial agreement on 16 November with a prominent European medicinal cannabis company.

The new contract could deliver revenue of up to £26m to Celadon over three years, with the initial product delivery expected in the second half of next year.

"The first supply of our pharmaceutical-grade product is a very significant milestone for both Celadon and the wider industry," said chief executive officer James Short.

"It has taken four years of hard work from our incredible team to get here.

"Having achieved our licences and secured our initial commercial contracts, today demonstrates that we are successfully supplying products and realising revenue."

Short said Celadon's focus on the highest standards of product quality was essential to meeting its customers' high expectations and building trust in the UK's medical cannabis market.

"Pleasingly, we are already seeing strong levels of demand for our product and, supported by the high barriers to entry for new producers, we remain confident in our long-term growth prospects."

At 1143 GMT, shares in Celadon Pharmaceuticals were up 0.52% at 115.6p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CEL Market Data

Currency UK Pounds
Share Price 13.75p
Change Today -1.75p
% Change -11.29 %
52 Week High 125.00p
52 Week Low 12.06p
Volume 332,250
Shares Issued 68.85m
Market Cap £9.47m
Beta 0.11
RiskGrade 111

CEL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
Market averageMarket averageMarket averageMarket averageMarket average
68.89% below the sector average68.89% below the sector average68.89% below the sector average68.89% below the sector average68.89% below the sector average
Price Trend
Market averageMarket averageMarket averageMarket averageMarket average
86.44% below the sector average86.44% below the sector average86.44% below the sector average86.44% below the sector average86.44% below the sector average
Income Not Available
Growth
Market averageMarket averageMarket averageMarket averageMarket average
52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average

CEL Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:06 183 @ 15.00p
16:06 66 @ 15.00p
16:06 25,000 @ 12.15p
15:36 67 @ 15.00p
15:18 3,365 @ 12.15p

CEL Key Personnel

CEO James Short
CFO Jonathan Turner

Top of Page